Travere Therapeutics (TVTX) Long-Term Debt Repayments (2013 - 2022)
Travere Therapeutics (TVTX) posted Long-Term Debt Repayments of $211.3 million for Q1 2022, up 1600839.39% on a QoQ basis from $13200.0 in Q1 2013.
Travere Therapeutics (TVTX) Long-Term Debt Repayments (2013 - 2022) Analysis & Trends
Travere Therapeutics' Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at $211.3 million for Q1 2022.
- Quarterly Long-Term Debt Repayments changed N/A year-over-year to $211.3 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $211.3 million (changed N/A YoY) and the FY2025 annual result came in at $68.9 million, changed N/A from the prior year.
- Long-Term Debt Repayments was $211.3 million for Q1 2022 at Travere Therapeutics, up from $13200.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $211.3 million in Q1 2022 and bottomed at $211.3 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.64 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 211.32 Mn |
| Mar 31, 2022 | 211.32 Mn |
| Mar 31, 2013 | 13,200.00 |
| Mar 31, 2013 | 13,200.00 |